Chronic otitis media treated topically with ciprofloxacin or tobramycin

Archives of Otolaryngology - Head and Neck Surgery

Volumn 123, Issue 10, 1997, Pages 1057-1060

  Fradis, Milo ^a,c   Brodsky, Alexander ^a,b   Ben David, Jacob ^b   Srugo, Isaac ^a   Larboni, Josef ^c   Podoshin, Ludwig ^a  

^a Otorhinolaryn Head/Neck Surg Dept   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OTITIS MEDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PSEUDOMONAS AERUGINOSA; TOPICAL DRUG ADMINISTRATION;

EID: 0030774106     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.1997.01900100031003     Document Type: Article

References (27)

1. Kenna MA, Bluestone CD, Reilly JS, Lusk RP. Medical management of chronic suppurative otitis media without cholesteatoma in children. Laryngoscope. 1986; 96:146-151.
2. Rorce RW, Hart MC, Plummer SA, Powell DA, Nahata MC. Topical ciprofloxacin for otorrhea after tympanostomy tube placement. Arch Oto/aryngol Head Neck Sur0.1995:121:880-884.
3. Brook I. Aerobic and anaerobic bacteriology of cholesteatoma. Laryngoscope. 1981;91:250-253.
4. Harker LA, Koontz FP. Bacteriology of cholesteatoma: clinical significance. Trans Am Acad Ophthalmol Otolaryngol. 1977;84:ORL-683-686.
5. Bluestone CD, Kenna MA. Chronic suppurative otitis media: antimicrobial therapy or surgery? PedlatrAnn. 1984:13:417-421.
6. Dohar JE, Kenna MA, Wadowsky RM. Therapeutic implications in the treatment of aura! Pseudomonas infections based on in vitro susceptibility patterns. Arch Otolaryngol Head Neck Surg. 1995;121:1022-1025.
7. Wright CG, Meyerhoff WL. Ototopical agents: efficacy or toxicity in humans. Ann Otol Rhinol Laryngol. 1988;97(suppl):30-32.
8. Wright CG, Halama AR, Meyerhoff WL Ototoxicity of an Ototopical preparation in a primate. Am J Otol. 1987:8:56-60.
9. Rudnick MD, Ginsberg IA, Huber PS. Aminoglycoside Ototoxicity following middle ear injection. Ann Otol Rhinol Laryngol. 1980;89(suppl):1-28.
10. Podoshin L, Fradis M, Ben-David J. Ototoxicity of ear drops in patients suffering from chronic otitis media. J Laryngol Otol. 1989:103:46-50.
11. Brummett RE, Himes D, Saine B, Vernon J. A comparative study of the Ototoxicity of tobramycin and gentamicin. Arch Otolaryngol. 1972:96:505-512.
12. Meyers RM. Ototoxic effects of gentamicin. Arch OMaryngol. 1970:92:160162.
13. Brownlee RE, Hulka GF, Prazma Y, Pillsbury HC III. Ciprofloxacin: use as a topical otic preparation. Arch Otolaryngol Head Neck Surg. 1992:118:392-396.
14. Piccirillo JF, Parnes SM. Ciprofloxacin for the treatment of chronic ear disease. Laryngoscope. 1989:99:510-513.
15. Esposito S, D'Errico G, Montanaro C. Topical and oral treatment of chronic otitis media with ciprofloxacin: a preliminary study. Arch Otolaryngol Head NeckSurg. 1990:116:557-559.
16. Esposito S, Noviello S, D'Errico G, Montanaro C. Topical ciprofloxacin vs intramuscular gentamicin for chronic otitis media. Arch Otolaryngol Head Neck Surg. 1992:118:842-844.
17. Tutkun A, Ozagar A, Koc A, Batman C, Üneri C, Sehitoglu MA. Treatment of chronic ear disease: topical ciprofloxacin vs topical gentamicin. Arch Otolaryngol Head NeckSurg. 1995;121:1414-1416.
18. Koestner JA. Ciprofloxacin: a new fluoroquinolone. Am J Med Sei. 1989;297: 128-131.
19. Bryan LE, Bedard J, Wong S, Chamberland S. Quinolone antimicrobial agents: mechanism of action and resistance development. Clin Invest Med. 1989:12:1419.
20. Crumplin GC, Kenwright M, Hirst T. Investigations into the mechanism of action of the antibacterial agent norfloxacin. JAntimicrob Chemother. 1984;13(suppl): 9-23.
21. Van de Heyning PH, Pattyn SR, Valcke HD. Ciprofloxacin in oral treatment of ear infection. Pharm Weekbl(Sci). 1986:8:63-66.
22. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate useemphasis on joint evaluation. Infection. 1991 ;19:289-296.
23. Black A, Redmond AO, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in paediatric patients. JAntimicrob Chemother. 1990;26(suppl):25-29.
24. Courvalin P. Plasmid-mediated 4-quinolone resistance: a real or apparent absence? Antimicrob Agents Chemother. 1990:34:681-684.
25. Raviglione MC, Boyle JF, Mariuz P, Pablos-Mendez A, Cortes H, Merlo A. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother. 1990:34:2050-2054.
26. Tong MCF, Woo JKS, Van Hasselt ÇA. A double blind comparative study of ofloxacin otic drops versus neomycin, polymyxin B, hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. J Laryngol Otol. 1996; 110:309-314.
27. Yuen PW, Lau SK, Chau PY, et al. Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study. Am J Otol. 1994;15: 670-673.